Marie Anne Hospital1, Norbert Vey2. 1. Hematology Department, Institut Paoli-Calmettes, Marseille, France. 2. Aix-Marseille Univ, Inserm, CNRS, CRCM, Institut Paoli-Calmettes, 232 Bvd Sainte Marguerite, 13009, Marseille, France. veyn@ipc.unicancer.fr.
Abstract
PURPOSE OF REVIEW: To understand how myelodysplastic syndromes (MDS) transform to AML and to describe how transformation can be predicted and prevented. RECENT FINDINGS: Recent genomic analyses have shown that MDS progression to AML is associated with clonal expansion and clonal evolution. Mutation profiles of MDS change during progression and new mutations in signaling genes and transcription factors emerge. AML transformation can be predicted by several parameters including International Prognostic Scoring System IPSS risk category and transfusion requirements. The prognostic relevance of the acquisition of some gene mutations (i.e., IDH1 and 2, CBL, FT3, RAS, NPM1, TP53, and ASXL1) has to be prospectively validated. The most effective preventive therapy for AML transformation is allogeneic stem cell transplantation. Hypomethylating agents have been associated with prolonged time to AML transformation even in patients who did not achieve an objective response. The recent progress in the understanding of the molecular events leading to transformation and the event of new effective therapies open new avenues for a better prediction and prevention of AML transformation in patients with MDS.
PURPOSE OF REVIEW: To understand how myelodysplastic syndromes (MDS) transform to AML and to describe how transformation can be predicted and prevented. RECENT FINDINGS: Recent genomic analyses have shown that MDS progression to AML is associated with clonal expansion and clonal evolution. Mutation profiles of MDS change during progression and new mutations in signaling genes and transcription factors emerge. AML transformation can be predicted by several parameters including International Prognostic Scoring System IPSS risk category and transfusion requirements. The prognostic relevance of the acquisition of some gene mutations (i.e., IDH1 and 2, CBL, FT3, RAS, NPM1, TP53, and ASXL1) has to be prospectively validated. The most effective preventive therapy for AML transformation is allogeneic stem cell transplantation. Hypomethylating agents have been associated with prolonged time to AML transformation even in patients who did not achieve an objective response. The recent progress in the understanding of the molecular events leading to transformation and the event of new effective therapies open new avenues for a better prediction and prevention of AML transformation in patients with MDS.
Authors: M Robin; R Porcher; W Zinke-Cerwenka; A van Biezen; L Volin; G Mufti; C Craddock; J Finke; C Richard; J Passweg; A Peniket; J Maertens; G Sucak; T Gedde-Dahl; A Vitek; A Nagler; D Blaise; D Beelen; N Maillard; R Schwerdtfeger; T de Witte; N Kroger Journal: Bone Marrow Transplant Date: 2017-07 Impact factor: 5.483
Authors: Philippe Guardiola; Volker Runde; Andrea Bacigalupo; Tapani Ruutu; Franco Locatelli; Marc A Boogaerts; Antonio Pagliuca; Jan J Cornelissen; Harry C Schouten; Enric Carreras; Jürgen Finke; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Eliane Gluckman; Theo M de Witte Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: C P Leith; K J Kopecky; J Godwin; T McConnell; M L Slovak; I M Chen; D R Head; F R Appelbaum; C L Willman Journal: Blood Date: 1997-05-01 Impact factor: 22.113
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Pearlie K Epling-Burnette; Fanqi Bai; Jeffrey S Painter; Dana E Rollison; Helmut R Salih; Matthias Krusch; Jianxiang Zou; Edna Ku; Bin Zhong; David Boulware; Lynn Moscinski; Sheng Wei; Julie Y Djeu; Alan F List Journal: Blood Date: 2007-03-06 Impact factor: 22.113
Authors: Johannes M Giesinger; Giorgio La Nasa; Francesco Sparano; Matthias Angermeyer; Emanuela Morelli; Olga Mulas; Fabio Efficace; Giovanni Caocci Journal: Clin Pract Epidemiol Ment Health Date: 2021-12-31